- Investments (#)(active tab)
- Investments (USD)
- Transactions
- Companies
- Investors
- Acquirers
- Industry map
- Valuations
Investments (#)
Investments (USD)
Transactions
Recent transactions in the domain of 7210 Research and experimental development on natural sciences and engineering
| Company | Country | Funding round | Date | |
|---|---|---|---|---|
|
Parse Biosciences Provider of single-cell sequencing solutions. |
United States | Series C USD 50,000,000 (USD 50,000,000) |
15 Dec 2023 |
|
|
Parse Biosciences Provider of single-cell sequencing solutions. |
United States | Debt |
15 Dec 2023 |
|
Vivodyne Inc Philadelphia-based biotech that tests its drug candidates on lab-grown human organs. |
United States | Seed USD 38,000,000 (USD 38,000,000) |
22 Nov 2023 |
|
Osium AI French AI startup focused on material sciences R&D. |
France | Seed USD 2,600,000 (USD 2,600,000) |
22 Nov 2023 |
|
|
Parse Biosciences Provider of single-cell sequencing solutions. |
United States | N/A USD 7,000,000 (USD 7,000,000) |
27 Jan 2021 |
|
Abalone Bio Antibody drug discovery. |
United States | Seed |
31 Dec 2020 |
|
Science Exchange Inc Online marketplace for scientific collaboration where researchers can order experiments from the world's best laboratories. |
United States | N/A USD 20,000,000 (USD 20,000,000) |
16 Oct 2019 |
|
Quell Therapeutics Ltd Developer of engineered T regulatory cell therapies. |
United Kingdom | Series A GBP 35,000,000 |
29 Mar 2019 |
|
Cambridge Cancer Genomics Ltd CCG.ai empowers clinicians to make personalised treatment strategies. |
United Kingdom | Seed |
31 Dec 2017 |
|
Ginkgo Bioworks Inc DNA design company. |
United States | Series D USD 275,000,000 (USD 275,000,000) at USD 1,300,000,000 (USD 1,300,000,000) valuation. |
14 Dec 2017 |
|
Armo BioSciences Inc Late-stage immuno-oncology company. |
Series C-1 USD 67,000,000 (USD 67,000,000) |
1 Sep 2017 | |
|
EpimAb Biotherapeutics Biopharmaceutical company focused on bispecific antibodies. |
Series A USD 25,000,000 (USD 25,000,000) |
25 Apr 2017 | |
|
Oxford Nanopore Technologies Ltd Developing the GridION system, a new generation of technology that uses nanopores - very small holes created in electrically resistant membranes. |
United Kingdom | Venture GBP 100,000,000 at GBP 1,150,000,000 valuation. |
12 Dec 2016 |
|
Novogene Technology Co Ltd Provider of genomic services. |
China | Series B CNY 515,000,000 (USD 75,000,000) |
1 Dec 2016 |
|
Tetra Discovery Partners Inc Biotechnology company developing treatments for Alzheimer's disease and other brain disorders. |
United States | Series A USD 5,000,000 (USD 5,000,000) |
30 Nov 2016 |
|
NBE-Therapeutics AG Biotech company focused on developing antibody-based treatments for cancer patients. |
Switzerland | Series B CHF 20,000,000 (USD 20,500,000) |
8 Nov 2016 |
|
Genomics Medicine Ireland Ltd Dublin-based life sciences startup. |
Ireland | Series A USD 40,000,000 (USD 40,000,000) |
26 Oct 2016 |
|
Science 37 Inc Provider of technology enabled clinical research solutions. |
Series B USD 31,000,000 (USD 31,000,000) |
18 Oct 2016 | |
|
|
ReadCoor |
Series A USD 23,000,000 (USD 23,000,000) |
29 Sep 2016 | |
|
Mitra Biotech Pvt Ltd Developer of personalized cancer treatments. |
India | Series B USD 27,400,000 (USD 27,400,000) |
29 Aug 2016 |
|
Medivation Inc |
United States | Acquisition USD 14,000,000,000 (USD 14,000,000,000) |
22 Aug 2016 |
|
Avelas Biosciences Inc Provider of advance, new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons. |
United States | Series C USD 20,000,000 (USD 20,000,000) |
18 Aug 2016 |
|
PathGroup Inc Provider of comprehensive anatomic, clinical and molecular pathology services. |
United States | Acquisition |
1 Aug 2016 |
|
|
Ginkgo Bioworks Inc DNA design company. |
United States | Series C USD 100,000,000 (USD 100,000,000) |
8 Jun 2016 |
|
Empire Genomics LLC Molecular diagnostics company. |
United States | Venture USD 1,750,000 (USD 1,750,000) |
20 May 2016 |
|
Stemcentrx Inc Cancer drug development company. |
United States | Acquisition USD 10,200,000,000 (USD 10,200,000,000) at USD 10,200,000,000 (USD 10,200,000,000) valuation. |
28 Apr 2016 |
|
|
AMEE UK Ltd Develops the world's most comprehensive, accurate, and transparent calculation engine for quantifying Greenhouse Gases (GHGs). |
United Kingdom | Acquisition |
18 Nov 2015 |
|
|
Science 37 Inc Provider of technology enabled clinical research solutions. |
Series A USD 6,500,000 (USD 6,500,000) |
21 Oct 2015 | |
|
|
Oxford Nanopore Technologies Ltd Developing the GridION system, a new generation of technology that uses nanopores - very small holes created in electrically resistant membranes. |
United Kingdom | Venture GBP 70,000,000 at GBP 899,350,000 valuation. |
20 Jul 2015 |
|
Abcodia Ltd Clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer. |
United Kingdom | Series B GBP 5,250,000 (USD 8,000,000) |
18 May 2015 |
|
Green Biologics Ltd |
United Kingdom | Series C USD 42,000,000 (USD 42,000,000) |
21 Jan 2015 |
|
|
Green Biologics Ltd |
United Kingdom | Debt USD 34,000,000 (USD 34,000,000) |
21 Jan 2015 |
|
|
Blend Therapeutics Inc Biotechnology company pioneering controlled combination medicines that overcome the limitations of conventional combination therapy. |
United States | Series B USD 21,000,000 (USD 21,000,000) |
7 Jan 2015 |
|
|
Abcodia Ltd Clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer. |
United Kingdom | Venture GBP 100,000 |
1 Nov 2014 |
|
Lumos Labs Inc Web-based provider of scientifically-tested brain training games |
United States | Secondary |
1 Nov 2014 |
|
Inivata Ltd Clinical cancer genomics company focused on harnessing the potential of circulating tumor DNA (ctDNA) analysis to improve cancer testing and treatment |
United Kingdom | N/A GBP 4,000,000 |
23 Sep 2014 |
|
|
Avelas Biosciences Inc Provider of advance, new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons. |
United States | Series B USD 7,400,000 (USD 7,400,000) |
10 Sep 2014 |
|
|
Stemcentrx Inc Cancer drug development company. |
United States | Series G USD 250,000,000 (USD 250,000,000) |
1 Sep 2014 |
|
|
Oxford Nanopore Technologies Ltd Developing the GridION system, a new generation of technology that uses nanopores - very small holes created in electrically resistant membranes. |
United Kingdom | Venture GBP 35,000,000 at GBP 609,720,000 valuation. |
12 Aug 2014 |
|
|
GeneWeave Biosciences Inc Developer of a platform for the rapid detection of infectious disease. |
United States | Series B USD 12,000,000 (USD 12,000,000) |
11 Jun 2014 |
|
|
Idenix Pharmaceuticals Inc |
United States | Acquisition USD 3,850,000,000 (USD 3,850,000,000) at USD 3,850,000,000 (USD 3,850,000,000) valuation. |
9 Jun 2014 |
|
|
Lumos Labs Inc Web-based provider of scientifically-tested brain training games |
United States | Secondary |
1 Jun 2014 |
|
|
Stemcentrx Inc Cancer drug development company. |
United States | Series F USD 200,000,000 (USD 200,000,000) |
1 May 2014 |
|
|
Abcodia Ltd Clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer. |
United Kingdom | Venture GBP 100,000 |
1 Feb 2014 |
|
|
Avelas Biosciences Inc Provider of advance, new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons. |
United States | Series B USD 6,800,000 (USD 6,800,000) |
9 Jan 2014 |
|
|
NovellusDx Ltd Maximizing the Therapeutic Impact in Most Common Cancers |
Israel | Series A |
31 Dec 2013 |
|
|
Green Biologics Ltd |
United Kingdom | Series B GBP 15,400,000 |
2 Dec 2013 |
|
|
GenapSys Inc Developer of genomic testing systems. |
United States | Series B USD 37,000,000 (USD 37,000,000) |
14 Nov 2013 |
|
|
Green Biologics Ltd |
United Kingdom | Venture GBP 2,000,000 |
31 Jul 2013 |
|
Zyomyx Inc Developer of protein chips. |
United States | Venture USD 12,000,000 (USD 12,000,000) |
30 Jun 2013 |
Companies
Best funded companies in the domain of 7210 Research and experimental development on natural sciences and engineering
Cancer drug development company.
Investment themes:
DNA design company.
Investment themes:
A biotechnology company, develops medicines to treat cancer and fibrotic diseases
Singapore-based cancer therapeutics company which, focuses on the discovery, research, and clinical development of small molecule drugs.
Philadelphia-based biotech that tests its drug candidates on lab-grown human organs.
Investment themes:
Developer of genomic testing systems.
Investment themes:
Web-based provider of scientifically-tested brain training games
Investment themes:
Bopharmaceutical company, focuses on the identification, development, commercialization of therapeutic compounds for osteo-renal diseases treatment.
Investment themes:
Provider of single-cell sequencing solutions.
Investment themes:
Biotechnology company providing preconception and prenatal genetic testing services.
Provider of advance, new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons.
Online marketplace for scientific collaboration where researchers can order experiments from the world's best laboratories.
Investment themes:
A biotechnology company focused on developing new class of therapeutic compounds.
Developer of protein chips.
Investment themes:
Developer of a platform for the rapid detection of infectious disease.
Investment themes:
Genome wide product company for research and diagnostic applications
Biotechnology company pioneering controlled combination medicines that overcome the limitations of conventional combination therapy.
Investment themes:
Biotech company focused on developing antibody-based treatments for cancer patients.
Develops the world's most comprehensive, accurate, and transparent calculation engine for quantifying Greenhouse Gases (GHGs).
Drug development company focused on novel targets in cellular protein homeostasis pathways
Clinical stage company engaged in the commercial development of novel, scientifically validated tests for the early detection of cancer.
French AI startup focused on material sciences R&D.
Investment themes:
Biotechnology company developing treatments for Alzheimer's disease and other brain disorders.
A UK Regenerative Medicine Company product and services. IPO in February 2006. Presently known as Regenerative Medicine Assets Ltd.
Investors
Top investors in the domain of 7210 Research and experimental development on natural sciences and engineering
| Investor | Profile | Country | Investments | |
|---|---|---|---|---|
|
Alta Partners LP | Venture capital firm based in San Francisco which invests primarily in biotechnology and life science companies. | United States | 53 |
|
OrbiMed Advisors LLC | American investment firm focused on making public and private investments in the healthcare and biotechnology industries. | United States | 48 |
|
Healthcare Ventures LLC | Venture capital firm focused on life sciences companies in pre-clinical and early clinical stage. | United States | 44 |
|
Domain Associates LLC | Venture capital firm focused on life sciences companies. | United States | 44 |
|
Novartis Services Inc | United States | 42 | |
|
Polaris Venture Partners Inc | Multistage venture capital investors with focus Technology, Healthcare and Consumer | United States | 35 |
|
Venrock Associates | The venture capital arm of the Rockefeller Family. | United States | 34 |
|
Kleiner Perkins Caufield & Byers LLC | Venture capital firm. | United States | 31 |
|
Versant Ventures Management LLC | Venture capital firm focused on making investments in the healthcare and biotechnology industries. | United States | 31 |
|
Western Technology Investment | Venture debt firm investing debt and equity capital in venture-backed technology, healthcare and clean technology companies. | United States | 29 |
|
ARCH Venture Partners LP | Venture capital firm providing seed and early stage capital, with a special expertise in co-founding and building technology firms from startup | United States | 29 |
|
Rho Capital Partners | Venture capital firm that actively invests in companies related to technology, new media, cleaning technology and healthcare. | United States | 26 |
|
Pappas Ventures | United States | 25 | |
|
IP Group PLC | British-based Intellectual property business investing in technology companies, based in London, England. | United Kingdom | 25 |
|
Johnson & Johnson Innovation LLC | Accelerator of early-stage innovation worldwide that forms collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. | United States | 24 |
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | 24 |
|
BioEnterprise | United States | 23 | |
|
5AM Venture Management LLC | United States | 23 | |
|
Intersouth Partners | Venture capital firm based in Durham, North Carolina. | United States | 22 |
|
Bessemer Venture Partners | Early stage venture capital firm. | United States | 22 |
|
CHL Medical Partners | Venture capital firm focused on early-stage healthcare sectors. | United States | 22 |
|
Frazier Healthcare Ventures | Investment firm providing growth and venture capital to healthcare companies. | United States | 21 |
|
Essex Woodlands Health Ventures Inc | United States | 20 | |
|
Bay City Capital LLC | United States | 20 | |
|
MPM Capital | United States | 20 | |
|
Hercules Technology Growth Capital Inc | Specialised finance company providing debt and equity growth capital to technology-related companies at all stages of development. | United States | 19 |
|
Avalon Ventures | United States | 19 | |
|
Delphi Ventures Inc | Venture capital firm with a focus on early stage investing in medical devices and biotechnology | United States | 18 |
|
Quaker BioVentures Inc | United States | 17 | |
|
TPG Growth LLC | The middle market and growth equity investment platform of TPG. | United States | 17 |
|
Science Center Ventures | United States | 17 | |
|
Midven Ltd | United Kingdom | 17 | |
|
Atlas Venture | Early-stage venture capital firm that creates and invests in biotechnology startup companies in the US. | United States | 17 |
|
Y Combinator | American technology startup accelerator. | United States | 17 |
|
US Venture Partners. | Silicon Valley venture capital firm. | United States | 17 |
|
New Leaf Venture Partners | United States | 16 | |
|
WRF Capital | United States | 16 | |
|
InterWest Partners | Diversified venture capital firm based in Silicon Valley. | United States | 16 |
|
TPG Capital LP | Private equity firm | United States | 16 |
|
Sofinnova Ventures Inc | United States | 16 | |
|
MPM Asset Management LLC | United States | 16 | |
|
Canaan Partners | Venture capital firm with a focus on early stage technology and healthcare companies | United States | 15 |
|
Sutter Hill Ventures LP | Private equity firm based in Palo Alto, Clifornia. | United States | 15 |
|
Vivo Ventures LLC | United States | 15 | |
|
ProQuest Investments | United States | 14 | |
|
Ben Franklin Technology Partners of Southeastern Pennsylvania | Initiative of the Pennsylvania Department of Community and Economic Development. | United States | 14 |
|
RCT BioVentures | The vehicle through which Research Corporation Technologies invests in start-up or early-stage companies | United States | 14 |
|
TVM Capital Corp | United States | 14 | |
|
New Enterprise Associates Inc | Global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. | United States | 13 |
|
FirstMark Capital LLC | Venture capital firm | United States | 13 |
Acquirers
Top acquirers in the domain of 7210 Research and experimental development on natural sciences and engineering
| Investor | Profile | Country | Acquisitions | |
|---|---|---|---|---|
|
Ampersand Ventures | United States | 3 | |
|
Gilead Sciences Inc | A biopharmaceutical company that discovers, develops and commercializes therapeutics. | United States | 2 |
|
|
Alexion Pharmaceuticals Inc | Complement inhibition for cardiovascular and inflammatory diseases. | United States | 2 |
|
Abbvie Inc | United States | 2 | |
|
|
Invitrogen Corp | United States | 2 | |
|
Abcam PLC | Abcam plc is a producer and distributor of research-grade antibodies and associated products. | United States | 1 |
|
|
Biogen Idec Inc | United States | 1 | |
|
|
Hologic Inc | Women health company | United States | 1 |
|
Amgen Inc | United States | 1 | |
|
|
Vayon Group | 1 | ||
|
|
Thermo Fisher Scientific Inc | United States | 1 | |
|
|
MacroGenics Inc | Biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases. | United States | 1 |
|
|
Swedish Orphan Biovitrum AB | Swedish pharmaceutical company with a product portfolio consisting of some 60 orphan and specialty pharmaceuticals | Sweden | 1 |
|
|
Agilent Technologies Inc | 1 | ||
|
Merck & Co | United States | 1 | |
|
|
Human Genome Sciences Inc | United States | 1 | |
|
|
Pi Ltd | 1 | ||
|
|
IntegenX Inc | Developing equipment for molecular diagnostics | United States | 1 |
|
|
Alkermes Inc | Ireland | 1 | |
|
|
Syngenta International AG | Switzerland | 1 | |
|
|
Bessemer Venture Partners | Early stage venture capital firm. | United States | 1 |
|
Pfizer Inc | United States | 1 | |
|
|
Cephalon Inc | Global biopharmaceutical company dedicated to discovering, developing and bringing to market medications. | United States | 1 |
|
|
Sanofi Aventis | 1 | ||
|
|
Johnson & Johnson Innovation LLC | Accelerator of early-stage innovation worldwide that forms collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. | United States | 1 |
Industry map
7210 Research and experimental development on natural sciences and engineering industry map
Valuations
7210 Research and experimental development on natural sciences and engineering selected pre-money valuations (USD)
| Funding round | Median | Average | Minimum | Maximum | Sample size |
|---|---|---|---|---|---|
| Series D | 1,300,000,000 | 1,300,000,000 | 1,300,000,000 | 1,300,000,000 | 1 |
| Acquisition | 3,700,000,000 | 5,606,428,571 | 170,000,000 | 20,000,000,000 | 7 |
| 170,000,000 | 20,000,000,000 | 8 |